Related Experiment Video
Updated: Apr 16, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma
Alexios Matikas1, Dimitrios Mavroudis
1Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece.
Abstract:
The treatment of metastatic melanoma is rapidly evolving. The discovery of BRAF and MEK inhibitors was an important milestone. Unfortunately, although response rates are high, disease progression is universal. Despite the success of IL-2 and adjuvant IFL-α2b, these two agents remained the only approved immunotherapy approaches. In recent years, the use of immunotherapy has drawn attention with the recognition of the mechanisms of tumor immune evasion. Blockade of these mechanisms may improve outcomes. However, the potential adverse events, the optimal use of these modalities, the high cost and the absence of predictive markers remain unmet challenges. Herein, we review the immunotherapy strategies in melanoma, either approved or under evaluation, and present the relevant data concerning their efficacy and safety.
Insights
Melanoma treatment advances include targeted therapies like BRAF/MEK inhibitors and immunotherapies. While effective, challenges like universal progression and adverse events persist, necessitating further research for improved melanoma outcomes.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Metastatic melanoma treatment is evolving rapidly.
- BRAF and MEK inhibitors offer high response rates but universal disease progression.
- Interleukin-2 (IL-2) and Interferon-alfa-2b (IFN-α2b) are established immunotherapy options.
Purpose of the Study:
- To review current and emerging immunotherapy strategies for melanoma.
- To present efficacy and safety data for approved and investigational immunotherapies.
- To highlight challenges in melanoma immunotherapy, including adverse events, cost, and predictive markers.
Main Methods:
- Literature review of approved and investigational immunotherapies for melanoma.
- Analysis of clinical trial data regarding treatment efficacy and safety.
- Discussion of tumor immune evasion mechanisms and their blockade.
Main Results:
- Targeted therapies (BRAF/MEK inhibitors) show initial high response rates but limited durability.
- Immunotherapy, including IL-2 and IFN-α2b, has shown success but faces challenges.
- Newer immunotherapies targeting immune evasion mechanisms are under evaluation.
Conclusions:
- Despite advances, universal disease progression remains a challenge in metastatic melanoma.
- Optimizing immunotherapy use, managing adverse events, and identifying predictive markers are critical unmet needs.
- Further research into novel immunotherapy strategies is essential for improving patient outcomes in melanoma.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...